Skip to main content



Local Cdiff information for Utah

Utah

Learn about C. diff providers, regulation, clinical trials, and advocacy efforts in Utah.



Local Cdiff information for Utah

Utah

Learn about C. diff providers, regulation, clinical trials, and advocacy efforts in Utah.

Providers

Andrew M. Skinner, MD

Infectious Diseases

University of Utah Health

50 North Medical Drive
Salt Lake City, Utah 84132

(801) 581-2121

VISIT WEBSITE>

M. Kyle Jensen, MD, MS

Pediatric Gastroenterology

Primary Children’s Pediatric GI
81 Mario Capecchi Dr.
Salt Lake City, Utah 84113

Phone: 801-213-3599
Fax: 801-587-7539

Pediatrics Only
FMT Provider

VISIT WEBSITE>

Regulation

C. diff Infections

Total Reported Cases: 348
Hospital Onset: 348
Community Onset: Not reported
Related Deaths: Not reported

Available Reports

Annual Progress based on SIR: 0.74
CDC STATE PROGRESS REPORT >
STATE REPORTING >

State Reporting Laws

Data Submission Required: Yes
Data Publicly Available: Yes
Data Validated: Yes
Facility-specific Data Publicly Reported: Yes
LTC Facility Submission Required: No
LTC Facility Data Publicly Reported: No
Law/Regulation: HB55
STATUTE >

State Contact

Sherry Varley RN,CIC
Infection Preventionist, Healthcare Associated Infections Program Coordinator
Utah Dept of Health
Bureau of Epidemiology
288 North 1460 West, 2nd Floor
Salt Lake City, 84114
(801) 538-6284
(801) 538-9115
EMAIL SHERRY VARLEY RN,CIC >

CLINICAL TRIALS

RESTORATiVE303

Official Title: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of VE303 for Prevention of Recurrent Clostridioides Difficile Infection
Trial No. NCT06237452
Type: Interventional
Recruitment: Recruiting
Sponsor: Vedanta Biosciences, Inc
Contact: Mary Garfield
EMAIL >
Gender: All
Age: 12 Years and older
Vedanta Biosciences has teamed up with Science37 to provide a site-less, decentralized approach. This means the study can be done remotely and the product comes to you, in your home. This allows applicants who are not near a study site or unable to travel to participate and receive treatment. You can sign up for the decentralized study here.

BEETHOVEN

Official Title: A PHASE 3, PLACEBO-CONTROLLED, DOUBLE-BLINDED, RANDOMIZED STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF A CLOSTRIDIOIDES DIFFICILE VACCINE IN ADULTS 65 YEARS OF AGE AND OLDER
Trial No. NCT07282665
Type: Interventional
Recruitment: Recruiting
Sponsor: Pfizer
Contact: See trial website for site-specific contacts
Gender: All
Age: 65 Years and older